Increase of Phosphatase and Tensin Homolog by Silymarin to Inhibit Human Pharynx Squamous Cancer

Overview

Journal J Med Food

Specialty Nutritional Sciences

Date 2013 Aug 6

PMID 23909904

Citations 11

Authors

Chin-Hui Su

Li-Jen Chen

Jyh Fei Liao

Juei-Tang Cheng

Affiliations

Soon will be listed here.

Abstract

Silymarin is an active principle from the seeds of the milk thistle plant and is widely used as a hepatoprotective gent due to its antioxidant-like activity. In the present study, we evaluated the potential efficacy of silymarin against oral cancer and investigated its possible mechanism of action. Cell viability assay and western blotting analyses were used to identify silymarin-induced apoptotic cell death in human pharynx squamous cell carcinoma (FaDu) cells. The short interfering RNA (siRNA) is used to confirm the role of phosphatase and tensin homolog (PTEN) in silymarin-induced apoptosis. Treatment of FaDu cells with silymarin resulted in a significant decrease in cell viability (up to 70%). Silymarin inhibited the phosphorylation of Akt (over 10-fold) with an increase in expression of PTEN (five to sixfold). Consequently, the level of Bcl-2 expression was decreased five to sixfold and caspase 3 activated to induce apoptosis. Treatment with siRNA specific to PTEN gene diminished the action of silymarin. The results suggest that silymarin inhibits the Akt signaling pathway by increasing PTEN expression in FaDu cells and directly affects Bcl-2 family members. Also, we demonstrated the inhibitory activity of silymarin for oral cancer is related to cell survival. These mechanisms may in part explain the actions of silymarin and provide a rationale for the development of silymarin as an anticancer agent.

Citing Articles

Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases.

Han J, Lee E, Park W, Ha K, Chung H Front Pharmacol. 2023; 14:1275000.

PMID: 37915411 PMC: 10616500. DOI: 10.3389/fphar.2023.1275000.

Silymarin inhibits the progression of Ehrlich solid tumor via targeting molecular pathways of cell death, proliferation, angiogenesis, and metastasis in female mice.

Amer M, Amer M, Othman A, Elsayed D, El-Missiry M, Ammar O Mol Biol Rep. 2022; 49(6):4659-4671.

PMID: 35305227 DOI: 10.1007/s11033-022-07315-2.

Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions.

Koltai T, Fliegel L J Evid Based Integr Med. 2022; 27:2515690X211068826.

PMID: 35018864 PMC: 8814827. DOI: 10.1177/2515690X211068826.

Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells.

Kaipa J, Starkuviene V, Erfle H, Eils R, Gladilin E PeerJ. 2020; 8:e10373.

PMID: 33362957 PMC: 7749657. DOI: 10.7717/peerj.10373.

Expression level of NEAT1 differentiates benign and malignant thyroid nodules by regulating NEAT1/miR‑9/PTEN and NEAT1/miR‑124/PDCD6 signalling.

Zhao L, Zhou N, Zhao P Int J Mol Med. 2020; 46(5):1661-1670.

PMID: 32901835 PMC: 7521579. DOI: 10.3892/ijmm.2020.4721.

References

Zhong X, Zhu Y, Lu Q, Zhang J, Ge Z, Zheng S . Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology. 2006; 227(3):211-6. DOI: 10.1016/j.tox.2006.07.021. View

Nukatsuka M, Saito H, Sakamoto K, Nakagawa F, Uchida J, Kobunai T . Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. Anticancer Res. 2012; 32(7):2807-12. View

Ramasamy K, Agarwal R . Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008; 269(2):352-62. PMC: 2612997. DOI: 10.1016/j.canlet.2008.03.053. View

Workman P, Clarke P, Raynaud F, van Montfort R . Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010; 70(6):2146-57. PMC: 3242038. DOI: 10.1158/0008-5472.CAN-09-4355. View

Singh R, Agarwal R . A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res. 2004; 555(1-2):21-32. DOI: 10.1016/j.mrfmmm.2004.05.017. View

Lu Y, Lin Y, Lapushin R, Cuevas B, Fang X, Yu S . The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene. 1999; 18(50):7034-45. DOI: 10.1038/sj.onc.1203183. View

Franke T, Cantley L . Apoptosis. A Bad kinase makes good. Nature. 1997; 390(6656):116-7. DOI: 10.1038/36442. View

Katiyar S, Roy A, Baliga M . Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther. 2005; 4(2):207-16. View

Peyrou M, Bourgoin L, Foti M . PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. Dig Dis. 2010; 28(1):236-46. DOI: 10.1159/000282095. View

10.

Scudiero D, Shoemaker R, Paull K, Monks A, Tierney S, Nofziger T . Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988; 48(17):4827-33. View

11.

Franke T, Hornik C, Segev L, Shostak G, Sugimoto C . PI3K/Akt and apoptosis: size matters. Oncogene. 2003; 22(56):8983-98. DOI: 10.1038/sj.onc.1207115. View

12.

Kroll D, Shaw H, Oberlies N . Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007; 6(2):110-9. DOI: 10.1177/1534735407301825. View

13.

Chen P, Hsieh Y, Chiang C, Chiou H, Yang S, Chu S . Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res. 2006; 85(3):220-5. DOI: 10.1177/154405910608500303. View

14.

Yoon Y, Kim Y, Jeon W, Park H, Sung H . Tanshinone IIA isolated from Salvia miltiorrhiza BUNGE induced apoptosis in HL60 human premyelocytic leukemia cell line. J Ethnopharmacol. 2000; 68(1-3):121-7. DOI: 10.1016/s0378-8741(99)00059-8. View

15.

Feher J, Lengyel G . [Silymarin in the treatment of chronic liver diseases: past and future]. Orv Hetil. 2008; 149(51):2413-8. DOI: 10.1556/OH.2008.28519. View

16.

Matsuda T, Ferreri K, Todorov I, Kuroda Y, Smith C, Kandeel F . Silymarin protects pancreatic beta-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology. 2004; 146(1):175-85. DOI: 10.1210/en.2004-0850. View

17.

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

18.

Yu H, Chen L, Cheng K, Li Y, Yeh C, Cheng J . Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog. Phytother Res. 2011; 26(5):709-15. DOI: 10.1002/ptr.3618. View

19.

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

20.

Poliseno L, Salmena L, Zhang J, Carver B, Haveman W, Pandolfi P . A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465(7301):1033-8. PMC: 3206313. DOI: 10.1038/nature09144. View